In conclusion, GAS5 represses the growth of breast cancer through regulating the IGF2BP2/QKI pathway, and this inhibitory effect is modulated by FTO-mediated m6A modification, suggesting that the FTO/GAS5/IGF2BP2/QKI pathway may be a potential target for breast cancer treatment. This evidence concerns the gene GAS5 and breast carcinoma.